InflaRx To Present Data From Phase 2a Clinical Study Of Oral C5ar Inhibitor INF904 In Participants With Hidradenitis Suppurativa And Chronic Spontaneous Urticaria On Nov. 10
Benzinga Newsdesk 1 year ago
News
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical trial of oral C5aR inhibitor INF904 in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on Monday, November 10, 2025.